Efficacy and Safety of the Bruton Tyrosine Kinase Inhibitor Ibrutinib in Patients with Hairy Cell Leukemia: Stage 1 Results of a Phase 2 Study

被引：14
|
作者：
Jones, Jeffrey [1 ]
Andritsos, Leslie [2 ]
Kreitman, Robert J. [3 ]
Ravandi, Farhad [4 ]
Schiffer, Charles [5 ]
Call, Timothy G. [6 ]
Lozanski, Gerard [7 ]
Harris, Pamela [8 ]
Sexton, Jennifer [2 ]
Ruppert, Amy S. [2 ]
Grever, Michael R. [2 ]
机构：
[1] Ohio State Univ, Div Hematol, Dept Internal Med, Columbus, OH USA
[2] Ohio State Univ, Div Hematol, Columbus, OH USA
[3] Natl Canc Inst, Natl Inst Hlth, Mol Biol Lab, Bethesda, MD USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
[5] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[6] Mayo Clin, Div Hematol, Rochester, MN USA
[7] Ohio State Univ, Dept Pathol, Columbus, OH USA
[8] Natl Canc Inst, Canc Therapy Evaluat Program, Rockville, MD USA
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1215.1215
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1215
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience
    Ali, Naveed
    Malik, Faizan
    Jafri, Syed Imran Mustafa
    Naglak, Mary
    Sundermeyer, Mark
    Pickens, Peter V.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S53 - S61
  • [42] Therapeutic effect of ibrutinib, a selective Bruton's tyrosine kinase inhibitor, in orbital fibroblasts from patients with Graves' orbitopathy
    Park, Hyun Young
    Chae, Min Kyung
    Ko, JaeSang
    Kikkawa, Don O.
    Jang, Sun Young
    Yoon, Jin Sook
    PLOS ONE, 2022, 17 (12):
  • [43] Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy
    Eyre, Toby A.
    Walter, Harriet S.
    Iyengar, Sunil
    Follows, George
    Cross, Matthew
    Fox, Christopher P.
    Hodson, Andrew
    Coats, Josh
    Narat, Santosh
    Morley, Nick
    Dyer, Martin J. S.
    Collins, Graham P.
    HAEMATOLOGICA, 2019, 104 (02) : E68 - E71
  • [44] Safety and Efficacy of Poseltinib, Bruton's Tyrosine Kinase Inhibitor, in Patients With Rheumatoid Arthritis: A Randomized, Double-blind, Placebo-controlled, 2-part Phase II Study
    Genovese, Mark C.
    Spindler, Alberto
    Sagawa, Akira
    Park, Won
    Dudek, Anna
    Kivitz, Alan
    Chao, Jeannie
    Chan, Lai Shan Melanie
    Witcher, Jennifer
    Barchuk, William
    Nirula, Ajay
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 969 - 976
  • [45] Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
    Advani, Ranjana H.
    Buggy, Joseph J.
    Sharman, Jeff P.
    Smith, Sonali M.
    Boyd, Thomas E.
    Grant, Barbara
    Kolibaba, Kathryn S.
    Furman, Richard R.
    Rodriguez, Sara
    Chang, Betty Y.
    Sukbuntherng, Juthamas
    Izumi, Raquel
    Hamdy, Ahmed
    Hedrick, Eric
    Fowler, Nathan H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (01) : 88 - 94
  • [46] Design of a phase II dose range finding, efficacy and safety study of the Bruton's tyrosine kinase inhibitor evobrutinib (M2951) in relapsing multiple sclerosis patients
    Montalban, X.
    Bojanowski, J.
    Martin, E.
    Willmer, J.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 324 - 324
  • [47] A pilot study of the efficacy of a bruton's tyrosine kinase inhibitor in the treatment of dogs with pemphigus foliaceus
    Murrell, D.
    Gourlay, S. M.
    Hill, R. J.
    Bisconte, A.
    Francesco, M.
    Smith, P.
    Karr, D.
    Outerbridge, C.
    Varjonen, K.
    Goodale, E. C.
    Borjesson, D.
    Werth, V. P.
    Nuun, P. A.
    White, S. D.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2017, 58 : 73 - 73
  • [48] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
    Tiacci, Enrico
    De Carolis, Luca
    Simonetti, Edoardo
    Merluzzi, Mara
    Bennati, Antonio
    Perriello, Vincenzo Maria
    Pucciarini, Alessandra
    Santi, Alessia
    Venanzi, Alessandra
    Pettirossi, Valentina
    Schiavoni, Gianluca
    Tasselli, Luisa
    Ascani, Stefano
    Volpetti, Stefano
    Falini, Brunangelo
    LEUKEMIA, 2021, 35 (11) : 3314 - 3318
  • [49] The Bruton tyrosine kinase inhibitor ibrutinib abrogates triggering receptor on myeloid cells 1-mediated neutrophil activation
    Stadler, Nicole
    Hasibeder, Astrid
    Lopez, Pamela Aranda
    Teschner, Daniel
    Desuki, Alexander
    Kriege, Oliver
    Weber, Alexander N. R.
    Schulz, Christoph
    Michel, Christian
    Hess, Georg
    Radsak, Markus P.
    HAEMATOLOGICA, 2017, 102 (05) : E191 - E194
  • [50] Safety and efficacy of the BRAF inhibitor dabrafenib in relapsed or refractory hairy cell leukemia: a pilot phase-2 clinical trial
    Enrico Tiacci
    Luca De Carolis
    Edoardo Simonetti
    Mara Merluzzi
    Antonio Bennati
    Vincenzo Maria Perriello
    Alessandra Pucciarini
    Alessia Santi
    Alessandra Venanzi
    Valentina Pettirossi
    Gianluca Schiavoni
    Luisa Tasselli
    Stefano Ascani
    Stefano Volpetti
    Brunangelo Falini
    Leukemia, 2021, 35 : 3314 - 3318
12345